Actinium to Present at the Canaccord Genuity 34th Annual Growth Conference on August 13th CEO to Provide Corporate Update on Late- and Mid-Stage Programs Focused on Acute Myeloid Leukemia and Other Advanced Cancers Canaccord Growth Conference 2014 Business Wire NEW YORK -- August 5, 2014 Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium, will present at the Canaccord Genuity 34^th Annual Growth Conference on Wednesday, August 13, 2014, at 9:30 a.m. ET in Boston, MA. The Company’s presentation is scheduled to begin at 9:30 a.m. ET and will be available via a live webcast. To access the live audio webcast, please log on through a link located in the Investors section of Actinium’s website at www.actiniumpharma.com under the Corporate Presentations tab. A replay will be available on the Actinium website within 48 hours and will be archived for a limited time. Dr. Dave and other members of the management team will be available for one-on-one meetings at the conference. Members of the investment community who are interested in meeting with management should contact their Canaccord Genuity representative, or Evan Smith, CFA of Actinium Pharmaceuticals, at 646-840-5442 or email@example.com. About Actinium Pharmaceuticals Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial. Forward-Looking Statement for Actinium Pharmaceuticals, Inc. This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Contact: Actinium Pharmaceuticals, Inc. Evan Smith, CFA, +1-646-840-5442 firstname.lastname@example.org VP Investor Relations and Finance
Actinium to Present at the Canaccord Genuity 34th Annual Growth Conference on August 13th
Press spacebar to pause and continue. Press esc to stop.